ITM Isotope Technologies Munich SE (ITM) and Radiopharm Theranostics have entered into an agreement under which ITM will supply that company with non-carrier-added lutetium-177 (n.c.a. Lu-177) for Radiopharm Theranostics' radiopharmaceutical therapies pipeline.
Radiopharm Theranostics will use ITM's n.c.a. Lu-177 in its development of RAD 204 (PD-L1-targeting nanobody, phase I), RAD 202 (HER2-targeting nanobody, phase I), and RV01 (B7-H3-targeting monoclonal antibody, preclinical), for the treatment of solid tumors, according to the two firms.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
